Sarepta Therapeutics Inc Stock Price, News & Analysis

Sarepta Therapeutics announced that the FDA has granted platform technology designation to the rAAVrh74 viral vector used in SRP-9003, their investigational gene therapy for limb-girdle muscular dystrophy type 2E/R4. This designation, among the first of its kind, recognizes the technology's reproducibility and adaptability across multiple therapeutic programs. The platform technology designation allows Sarepta to leverage prior data to support future drug applications, streamlining development and review processes. SRP-9003 is designed to deliver a full-length beta-sarcoglycan transgene using the MHCK7 promoter, targeting skeletal, diaphragm, and cardiac muscle. This is particularly crucial for LGMD2E patients who often face pulmonary or cardiac complications.

Sarepta Therapeutics (NASDAQ:SRPT) announced that the UK's Medicines & Healthcare products Regulatory Agency (MHRA) has allowed continued uninterrupted dosing of ELEVIDYS in the ENVISION Phase 3 study. The study evaluates this gene therapy treatment in non-ambulatory and older ambulatory individuals with Duchenne muscular dystrophy (DMD). ELEVIDYS is a single-dose, AAV-based gene therapy designed to address DMD's genetic cause through micro-dystrophin production. The therapy is approved in the US for DMD patients aged 4 and older, both ambulatory and non-ambulatory, with the latter approved under accelerated approval pending confirmatory trials. The press release details important safety information, including potential risks such as infusion-related reactions, liver injury, immune-mediated myositis, and myocarditis.

Sarepta Therapeutics (NASDAQ:SRPT) reported new results from the ENDEAVOR study of ELEVIDYS for Duchenne muscular dystrophy treatment. In cohort 6 (n=6) with 2-year-old patients, treatment demonstrated mean protein expression of 93.87% measured by western blot and 79.9% dystrophin positive fibers. Safety profile aligned with previous studies, with common side effects including nausea and vomiting. Two patients experienced elevated liver enzymes, which resolved with steroid treatment. Previously reported results from Cohort 4 (3-year-olds, n=7) showed 99.64% mean protein levels. Over 25 patients under age 4 have been treated in clinical studies. The company plans to meet with FDA next month to discuss expanding ELEVIDYS label to include younger patients.

Sarepta Therapeutics (SRPT) presented new data from Part 2 of the EMBARK study for ELEVIDYS, their approved gene therapy for Duchenne muscular dystrophy. The analysis focused on 8-9 year old patients (n=14) who received treatment after placebo in Part 1. At one year post-treatment, patients showed statistically significant improvements across key endpoints compared to controls: • 4.75 points improvement in North Star Ambulatory Assessment (P=0.0026) • 6.87 seconds better in time-to-rise from floor (P=0.0010) • 4.76 seconds improvement in 10-meter walk/run (P=0.0097) These results are particularly notable as they demonstrate functional improvements at an age when motor decline typically occurs in Duchenne patients. The two-year study data showed sustained micro-dystrophin expression from Week 12 to Week 64 in a subset of patients, with no new safety signals observed.

Sarepta Therapeutics (NASDAQ:SRPT) has received approval from Japan's MHLW for ELEVIDYS, a gene therapy treatment for Duchenne muscular dystrophy (DMD). This marks the first global approval for treating patients younger than 4 years old, covering ages 3 to under 8 years. The approval is based on positive efficacy and safety data from clinical studies, including two-year results from the Phase 3 EMBARK trial, which demonstrated significantly better motor function outcomes compared to controls. Through a collaboration with Roche, Sarepta will receive up to $103.5M in milestone payments. The therapy will be commercialized in Japan by Chugai Pharmaceuticals via its Roche alliance. ELEVIDYS is a single-dose, AAV-based gene therapy designed to address DMD's genetic cause through micro-dystrophin production in skeletal muscle.

Sarepta Therapeutics (NASDAQ:SRPT), a leader in precision genetic medicine for rare diseases, announced its senior management will participate in a fireside chat at the BofA Securities Health Care Conference. The event will take place at the Encore Hotel in Las Vegas on May 14, 2025, at 8:40 a.m. PT/11:40 a.m. ET.

The presentation will be available via webcast on Sarepta's investor relations website and will remain archived for 90 days. The company maintains leadership positions in Duchenne muscular dystrophy and limb-girdle muscular dystrophies, while developing a portfolio focused on muscle, central nervous system, and cardiac diseases.

Sarepta Therapeutics (SRPT) reported Q1 2025 financial results with total revenues of $744.9M, up 80% year-over-year. Net product revenues reached $611.5M, a 70% increase, with ELEVIDYS contributing $375.0M (180% growth) and PMO franchise at $236.5M. However, facing headwinds, Sarepta revised its 2025 revenue guidance down to $2.3-2.6B from $2.9-3.1B. The company reported a GAAP net loss of $447.5M. The quarter saw significant pipeline progress in limb-girdle muscular dystrophy programs, including advancement in SRP-9005 (LGMD2C/R5), completed enrollment in SRP-9004 (LGMD2D/R3) study, and completion of EMERGENE phase 3 trial for SRP-9003. Sarepta closed a global licensing agreement with Arrowhead Pharmaceuticals for multiple clinical and preclinical programs in muscle, CNS, and rare pulmonary disorders.

Cash position stood at $647.5M as of March 31, 2025, down from $1.5B at year-end 2024.

Sarepta Therapeutics (NASDAQ:SRPT), a leader in precision genetic medicine for rare diseases, has scheduled its first quarter 2025 financial results announcement. The results will be released after the Nasdaq Global Market closes on Tuesday, May 6, 2025, followed by a conference call at 4:30 p.m. E.T. to discuss the quarterly performance.

The event will be accessible through a live webcast on the investor relations section of Sarepta's website, with a replay available for one year. Phone participants must register online to receive dial-in details and a personal PIN for accessing the event.

Sarepta Therapeutics (NASDAQ:SRPT) announced significant progress in its limb-girdle muscular dystrophy (LGMD) pipeline programs. The FDA has cleared the company to proceed with dosing in Study SRP-9005-101 (COMPASS) for LGMD2C/R5, marking their fourth LGMD program to enter clinical trials.

The company has completed enrollment and dosing in Study SRP-9004-102 (DISCOVERY) for LGMD2D/R3. Additionally, enrollment and dosing are complete in the phase 3 EMERGENE trial of SRP-9003 for LGMD2E/R4, with data expected by mid-2025. The FDA has confirmed eligibility for accelerated approval, and Sarepta plans to submit a Biologics License Application in the second half of 2025.

These developments are significant as there are currently no disease-modifying treatments approved for any LGMD subtype. Sarepta's LGMD pipeline covers subtypes that represent over 70% of known LGMD cases.